[{"id":"955c5465-ea4e-4842-8504-e6f530022df5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07043270","created_at":"2025-07-05T13:59:36.534Z","updated_at":"2025-07-05T13:59:36.534Z","phase":"Phase 2","brief_title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","source_id_and_acronym":"NCT07043270","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-07-02"},{"id":"2451850f-5b0c-4c08-aeda-4faec51709a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045311","created_at":"2025-07-05T13:59:45.588Z","updated_at":"2025-07-05T13:59:45.588Z","phase":"Phase 2","brief_title":"JS207 Combination Therapy in Triple-negative Breast Cancer","source_id_and_acronym":"NCT07045311","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • bulumtatug fuvedotin (9MW2821)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 03/22/2028","primary_completion_date":" 03/22/2028","study_txt":" Completion: 03/22/2029","study_completion_date":" 03/22/2029","last_update_posted":"2025-07-01"},{"id":"5561c46c-9fe6-437d-a39f-ed6b0feba556","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998940","created_at":"2025-06-07T14:48:14.371Z","updated_at":"2025-06-07T14:48:14.371Z","phase":"Phase 3","brief_title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","source_id_and_acronym":"NCT06998940","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 01/06/2026","start_date":" 01/06/2026","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-05-31"},{"id":"f99e9a96-78aa-4611-a09e-0bb82a397f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06967103","created_at":"2025-06-07T15:00:18.246Z","updated_at":"2025-06-07T15:00:18.246Z","phase":"Phase 2","brief_title":"QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06967103","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/30/2029","study_completion_date":" 05/30/2029","last_update_posted":"2025-05-13"},{"id":"f43e758f-4bc3-4256-ae14-899721a6e9b8","acronym":"GALENT-BT","url":"https://clinicaltrials.gov/study/NCT06963060","created_at":"2025-09-07T01:31:36.203Z","updated_at":"2025-09-07T01:31:36.203Z","phase":"Phase 2","brief_title":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","source_id_and_acronym":"NCT06963060 - GALENT-BT","lead_sponsor":"Wei Gong","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 44","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-05-08"},{"id":"bf338af6-7bdc-4263-a249-2470acc07fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06860529","created_at":"2025-06-07T14:59:59.699Z","updated_at":"2025-06-07T14:59:59.699Z","phase":"Phase 2","brief_title":"Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06860529","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 357","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-03-06"},{"id":"056fe673-cdf1-43ac-850b-4889f543f569","acronym":"","url":"https://clinicaltrials.gov/study/NCT03169790","created_at":"2021-01-18T15:37:43.674Z","updated_at":"2025-02-25T12:26:42.620Z","phase":"Phase 1/2","brief_title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","source_id_and_acronym":"NCT03169790","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2025-02-24"},{"id":"d4921ecb-dbf8-4a8b-a82b-331ac066876f","acronym":"ACHIEVE Study","url":"https://clinicaltrials.gov/study/NCT06096844","created_at":"2023-10-24T15:13:40.333Z","updated_at":"2025-02-25T12:38:45.622Z","phase":"Phase 3","brief_title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","source_id_and_acronym":"NCT06096844 - ACHIEVE Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 304","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-24"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"44d24989-a21f-4511-a498-f631f60a4181","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554109","created_at":"2021-01-18T17:29:18.298Z","updated_at":"2025-02-25T13:39:37.796Z","phase":"Phase 2","brief_title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","source_id_and_acronym":"NCT03554109","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 02/09/2022","study_completion_date":" 02/09/2022","last_update_posted":"2025-02-21"},{"id":"913a7f90-f43b-43fc-9a5c-45399bce2739","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907475","created_at":"2021-01-18T19:14:04.518Z","updated_at":"2025-02-25T13:39:50.577Z","phase":"Phase 2","brief_title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)","source_id_and_acronym":"NCT03907475","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD4 • IL2","pipe":"","alterations":" ","tags":["TMB • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"29707765-41ef-4904-94a6-cabf9f766606","acronym":"IMpower030","url":"https://clinicaltrials.gov/study/NCT03456063","created_at":"2021-01-18T17:02:24.865Z","updated_at":"2025-02-25T14:01:22.616Z","phase":"Phase 3","brief_title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","source_id_and_acronym":"NCT03456063 - IMpower030","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" IRF1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IRF1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-19"},{"id":"65e873c4-e41a-4522-8b0f-ce3ec9de207d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00609791","created_at":"2021-01-18T02:15:51.515Z","updated_at":"2025-02-25T14:06:39.505Z","phase":"Phase 2","brief_title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer","source_id_and_acronym":"NCT00609791","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/11/2008","start_date":" 02/11/2008","primary_txt":" Primary completion: 10/25/2011","primary_completion_date":" 10/25/2011","study_txt":" Completion: 05/15/2025","study_completion_date":" 05/15/2025","last_update_posted":"2025-02-19"},{"id":"9cfc6cab-bd14-4a27-8da2-14e1f08db131","acronym":"","url":"https://clinicaltrials.gov/study/NCT01463072","created_at":"2021-01-18T06:05:14.850Z","updated_at":"2025-02-25T13:59:58.723Z","phase":"Phase 2","brief_title":"Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT01463072","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/19/2012","start_date":" 06/19/2012","primary_txt":" Primary completion: 05/17/2017","primary_completion_date":" 05/17/2017","study_txt":" Completion: 06/17/2025","study_completion_date":" 06/17/2025","last_update_posted":"2025-02-19"},{"id":"b2796697-f53f-4b0f-891f-ff27bfd09451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05852691","created_at":"2023-05-10T21:04:00.257Z","updated_at":"2025-02-25T14:09:43.602Z","phase":"Phase 2","brief_title":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05852691","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • ER • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2 • PD-L1 • ER • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"},{"id":"bb866355-1e34-4d35-9bb4-a41598c5e17e","acronym":"IMM1104-101","url":"https://clinicaltrials.gov/study/NCT05585320","created_at":"2022-10-18T14:57:21.622Z","updated_at":"2025-02-25T14:09:12.843Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05585320 - IMM1104-101","lead_sponsor":"Immuneering Corporation","biomarkers":" KRAS • HRAS • APC","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation","tags":["KRAS • HRAS • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • atebimetinib (IMM-1-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 10/31/2022","start_date":" 10/31/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"ca63580a-c74e-4b79-b0d5-8d419247f75b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03177291","created_at":"2021-01-18T15:40:02.831Z","updated_at":"2025-02-25T14:15:00.298Z","phase":"Phase 1","brief_title":"Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC","source_id_and_acronym":"NCT03177291","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 09/26/2017","start_date":" 09/26/2017","primary_txt":" Primary completion: 05/09/2021","primary_completion_date":" 05/09/2021","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-18"},{"id":"a5794ed7-ec20-4c8e-af55-9e059e2c03e3","acronym":"RASolute 302","url":"https://clinicaltrials.gov/study/NCT06625320","created_at":"2025-02-25T14:19:38.953Z","updated_at":"2025-02-25T14:19:38.953Z","phase":"Phase 3","brief_title":"Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06625320 - RASolute 302","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"40c7efdf-8bc2-49bd-8de1-be213f764540","acronym":"","url":"https://clinicaltrials.gov/study/NCT06825546","created_at":"2025-02-25T15:16:34.142Z","updated_at":"2025-02-25T15:16:34.142Z","phase":"Phase 2","brief_title":"Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT06825546","lead_sponsor":"Sir Run Run Shaw Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • icaritin (SNG-162)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-13"},{"id":"b91c94f1-41f7-4fe2-83f9-441496a86f3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919537","created_at":"2023-06-26T14:09:25.129Z","updated_at":"2025-02-25T15:13:34.765Z","phase":"Phase 1","brief_title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","source_id_and_acronym":"NCT05919537","lead_sponsor":"Hummingbird Bioscience","biomarkers":" ERBB3 • NRG1 • EGF","pipe":" | ","alterations":" NRG1 fusion","tags":["ERBB3 • NRG1 • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • albumin-bound paclitaxel • HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-13"},{"id":"5140cf2b-ceba-4625-9ec1-ad9d0bbb9e1b","acronym":"KEYVIBE 007","url":"https://clinicaltrials.gov/study/NCT05226598","created_at":"2025-02-25T15:19:31.574Z","updated_at":"2025-02-25T15:19:31.574Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)","source_id_and_acronym":"NCT05226598 - KEYVIBE 007","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 739","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 09/24/2024","primary_completion_date":" 09/24/2024","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2025-02-11"}]